Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blum, J. L.
Right arrow Articles by Griffin, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blum, J. L.
Right arrow Articles by Griffin, T.
Journal of Clinical Oncology, Vol 17, Issue 2 (February), 1999: 485
© 1999 American Society for Clinical Oncology

Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

Joanne L. Blum, Stephen E. Jones, Aman U. Buzdar, Patricia Mucci LoRusso, Irene Kuter, Charles Vogel, Bruno Osterwalder, Hans-Ulrich Burger, Cheryl Stoner Brown, Tom Griffin

From the Physician Reliance Network (PRN) Research, Baylor-Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, and M.D. Anderson Cancer Center, Houston, TX; Harper Hospital, Detroit, MI; Massachusetts General Hospital, Boston, MA; Cancer Center, North Miami Beach, FL; and Hoffman-LaRoche, Inc, Nutley, NJ.

Address reprint requests to Joanne L. Blum, MD, PhD, Physician Reliance Network Research, 3535 Worth St, Suite 230, Dallas, TX 75246.

PURPOSE: Capecitabine is a novel, oral, selectively tumor-activated fluoropyrimidine carbamate. This large multicenter phase II trial tested the efficacy and safety of twice-daily oral capecitabine at 2,510 mg/m2/d given for 2 weeks followed by a 1-week rest period and repeated in 3-week cycles, in patients with paclitaxel-refractory metastatic breast cancer.

PATIENTS AND METHODS: Patients were to have received at least two but not more than three prior chemotherapeutic regimens, one of which had to have contained paclitaxel given for metastatic disease. One hundred sixty-three patients were entered onto the study at 25 centers, and 162 patients received capecitabine. One hundred thirty-five patients had bidimensionally measurable disease, and 27 patients had assessable disease.

RESULTS: The overall response rate was 20% (95% confidence interval, 14% to 28%). All responding patients were resistant to or had failed paclitaxel, and all had received an anthracycline. Three complete responses were seen, with complete response durations of 106, 109, and 194+ days. Median duration of response was 8.1 months, median survival time was 12.8 months, and the median time to disease progression was 93 days. The most common treatment-related adverse events were hand-foot syndrome, diarrhea, nausea, vomiting, and fatigue. Diarrhea (14%) and hand-foot syndrome (10%) were the only treatment-related adverse events that occurred with grade 3 or 4 intensity in more than 10% of patients.

CONCLUSION: Capecitabine is an active drug in the treatment of paclitaxel-refractory metastatic breast cancer. It has a favorable toxicity profile with the added advantage of being an oral drug administered at home.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. Albanell, C. Montagut, E. T. Jones, L. Pronk, B. Mellado, J. Beech, P. Gascon, G. Zugmaier, M. Brewster, M. P. Saunders, et al.
A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors
Clin. Cancer Res., May 1, 2008; 14(9): 2726 - 2731.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
X. Pivot, P. Koralewski, J. L. Hidalgo, A. Chan, A. Goncalves, G. Schwartsmann, S. Assadourian, and J. P. Lotz
A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients
Ann. Onc., April 23, 2008; (2008) mdn171v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. A. Traina, M. Theodoulou, K. Feigin, S. Patil, K. L. Tan, C. Edwards, U. Dugan, L. Norton, and C. Hudis
Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer
J. Clin. Oncol., April 10, 2008; 26(11): 1797 - 1802.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Findlay, G. von Minckwitz, and A. Wardley
Effective oral chemotherapy for breast cancer: pillars of strength
Ann. Onc., February 1, 2008; 19(2): 212 - 222.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Sharma, J. M. Hoskins, L. P. Rivory, M. Zucknick, R. London, C. Liddle, and S. J. Clarke
Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients
Clin. Cancer Res., February 1, 2008; 14(3): 817 - 825.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. S. Thomas, H. L. Gomez, R. K. Li, H.-C. Chung, L. E. Fein, V. F. Chan, J. Jassem, X. B. Pivot, J. V. Klimovsky, F. H. de Mendoza, et al.
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
J. Clin. Oncol., November 20, 2007; 25(33): 5210 - 5217.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Diaz-Rubio, J. Tabernero, A. Gomez-Espana, B. Massuti, J. Sastre, M. Chaves, A. Abad, A. Carrato, B. Queralt, J. J. Reina, et al.
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
J. Clin. Oncol., September 20, 2007; 25(27): 4224 - 4230.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Bartsch, C. Wenzel, G. Altorjai, U. Pluschnig, M. Rudas, R. M. Mader, M. Gnant, C. C. Zielinski, and G. G. Steger
Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3853 - 3858.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Thomas, J. Tabernero, M. Fornier, P. Conte, P. Fumoleau, A. Lluch, L. T. Vahdat, C. A. Bunnell, H. A. Burris, P. Viens, et al.
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
J. Clin. Oncol., August 10, 2007; 25(23): 3399 - 3406.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Schaller, I. Fuchs, T. Gonsch, J. Weber, A. Kleine-Tebbe, P. Klare, H.-J. Hindenburg, V. Lakner, A. Hinke, and N. Bangemann
Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes
J. Clin. Oncol., August 1, 2007; 25(22): 3246 - 3250.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Verma and M. Clemons
First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy
Oncologist, July 1, 2007; 12(7): 785 - 797.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso
Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Oncologist, March 1, 2007; 12(3): 253 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L Gore, S. Holden, R. Cohen, M Morrow, A. Pierson, C. O'Bryant, M Persky, D Gustafson, C Mikule, S Zhang, et al.
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors
Ann. Onc., November 1, 2006; 17(11): 1709 - 1717.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. L. Blum, E. C. Dees, A. Chacko, L. Doane, S. Ethirajan, J. Hopkins, R. McMahon, S. Merten, A. Negron, M. Neubauer, et al.
Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast Cancer
J. Clin. Oncol., September 20, 2006; 24(27): 4384 - 4390.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
S. M Gressett, B. L Stanford, and F. Hardwicke
Management of hand-foot syndrome induced by capecitabine
Journal of Oncology Pharmacy Practice, September 1, 2006; 12(3): 131 - 141.
[Abstract] [PDF]

Home page
 Ann OncolHome page
R Leonard, J O'Shaughnessy, S Vukelja, V Gorbounova, C. Chan-Navarro, D Maraninchi, N Barak-Wigler, J. McKendrick, W. Harker, A. Bexon, et al.
Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?
Ann. Onc., September 1, 2006; 17(9): 1379 - 1385.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. Cameron, R. Bell, M. Aapro, and C. Zielinski
What Are the Current Standards of Care and Recent Developments in the Management of Breast Cancer?
Oncologist, September 1, 2006; 11(suppl_1): 1 - 3.
[Full Text] [PDF]

Home page
 The OncologistHome page
A. Wardley
Capecitabine: Expanding Options for the Treatment of Patients with Early or Locally Advanced Breast Cancer
Oncologist, September 1, 2006; 11(suppl_1): 20 - 26.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Gelmon, A. Chan, and N. Harbeck
The Role of Capecitabine in First-Line Treatment for Patients with Metastatic Breast Cancer
Oncologist, September 1, 2006; 11(suppl_1): 42 - 51.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. B. Ershler
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer.
Oncologist, April 1, 2006; 11(4): 325 - 335.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. X. Ma, P. Steen, K. M. Rowland, R. D. Niedringhaus, T. R. Fitch, J. W. Kugler, D. W. Hillman, E. A. Perez, J. N. Ingle, and A. A. Adjei
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
Ann. Onc., February 1, 2006; 17(2): 226 - 231.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Kurt, M. O Babaoglu, U. Yasar, A. Shorbagi, and N. Guler
Capecitabine-Induced Severe Hypertriglyceridemia: Report of Two Cases
Ann. Pharmacother., February 1, 2006; 40(2): 328 - 331.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. O'Shaughnessy
Extending Survival with Chemotherapy in Metastatic Breast Cancer
Oncologist, October 1, 2005; 10(suppl_3): 20 - 29.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Verma, M. Trudeau, G. Dranitsaris, M. Clemons, A. A. Joy, and J. R. MacKey
What Is the Best Chemotherapy Treatment Option for Anthracycline and Taxane Pretreated Metastatic Breast Cancer?
J. Clin. Oncol., September 1, 2005; 23(25): 6260 - 6260.
[Full Text] [PDF]

Home page
 Ann OncolHome page
B. T. Hennessy, A. M. Gauthier, L. B. Michaud, G. Hortobagyi, and V. Valero
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature
Ann. Onc., August 1, 2005; 16(8): 1289 - 1296.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Bocci, M. Tuccori, U. Emmenegger, V. Liguori, A. Falcone, R. S. Kerbel, and M. Del Tacca
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation
Ann. Onc., August 1, 2005; 16(8): 1243 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Beutel, H. Glen, P. Schoffski, J. Chick, S. Gill, J. Cassidy, and C. Twelves
Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors
Clin. Cancer Res., August 1, 2005; 11(15): 5487 - 5495.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Toi, T. Saeki, K. Aogi, M. Sano, K. Hatake, T. Asaga, Y. Tokuda, S. Mitsuyama, M. Kimura, T. Kobayashi, et al.
Late Phase II Clinical Study of Vinorelbine Monotherapy in Advanced or Recurrent Breast Cancer Previously Treated with Anthracyclines and Taxanes
Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 310 - 315.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Feliu, P. Escudero, F. Llosa, M. Bolanos, J.-M. Vicent, A. Yubero, J.-J. Sanz-Lacalle, R. Lopez, L. Lopez-Gomez, E. Casado, et al.
Capecitabine As First-Line Treatment for Patients Older Than 70 Years With Metastatic Colorectal Cancer: An Oncopaz Cooperative Group Study
J. Clin. Oncol., May 1, 2005; 23(13): 3104 - 3111.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Noguchi, H. Koyama, J. Uchino, R. Abe, S. Miura, K. Sugimachi, K. Akazawa, and O. Abe
Postoperative Adjuvant Therapy With Tamoxifen, Tegafur Plus Uracil, or Both in Women With Node-Negative Breast Cancer: A Pooled Analysis of Six Randomized Controlled Trials
J. Clin. Oncol., April 1, 2005; 23(10): 2172 - 2184.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Hamilton and G. Hortobagyi
Chemotherapy: What Progress in the Last 5 Years?
J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775.
[Full Text] [PDF]

Home page
 JCOHome page
K. D. Miller, L. I. Chap, F. A. Holmes, M. A. Cobleigh, P. K. Marcom, L. Fehrenbacher, M. Dickler, B. A. Overmoyer, J. D. Reimann, A. P. Sing, et al.
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
J. Clin. Oncol., February 1, 2005; 23(4): 792 - 799.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Welt, G. von Minckwitz, C. Oberhoff, D. Borquez, R. Schleucher, S. Loibl, A. Harstrick, M. Kaufmann, S. Seeber, and U. Vanhoefer
Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer
Ann. Onc., January 1, 2005; 16(1): 64 - 69.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Bernard-Marty, F. Cardoso, and M. J. Piccart
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Oncologist, November 1, 2004; 9(6): 617 - 632.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Keller, R. G. Mennel, V. A. Georgoulias, J.-M. Nabholtz, A. Erazo, A. Lluch, C. L. Vogel, M. Kaufmann, G. von Minckwitz, I. C. Henderson, et al.
Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer
J. Clin. Oncol., October 1, 2004; 22(19): 3893 - 3901.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. S. Hong, S. Y. Song, S. I. Lee, H. C. Chung, S. H. Choi, S. H. Noh, J. N. Park, J. Y. Han, J. H. Kang, K. S. Lee, et al.
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer
Ann. Onc., September 1, 2004; 15(9): 1344 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Perez, D. W. Hillman, J. A. Mailliard, J. N. Ingle, J. M. Ryan, T. R. Fitch, K. M. Rowland, C. G. Kardinal, J. E. Krook, J. W. Kugler, et al.
Randomized Phase II Study of Two Irinotecan Schedules for Patients With Metastatic Breast Cancer Refractory to an Anthracycline, a Taxane, or Both
J. Clin. Oncol., July 15, 2004; 22(14): 2849 - 2855.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. J. Gradishar, L. A. Meza, B. Amin, D. Samid, T. Hill, Y.-M. Chen, E. E. Lower, and P. K. Marcom
Capecitabine Plus Paclitaxel As Front-Line Combination Therapy for Metastatic Breast Cancer: A Multicenter Phase II Study
J. Clin. Oncol., June 15, 2004; 22(12): 2321 - 2327.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Cassidy, J. Tabernero, C. Twelves, R. Brunet, C. Butts, T. Conroy, F. Debraud, A. Figer, J. Grossmann, N. Sawada, et al.
XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., June 1, 2004; 22(11): 2084 - 2091.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. A. Rich, R. C. Shepard, and S. T. Mosley
Four Decades of Continuing Innovation With Fluorouracil: Current and Future Approaches to Fluorouracil Chemoradiation Therapy
J. Clin. Oncol., June 1, 2004; 22(11): 2214 - 2232.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Kurt, O. O. Eren, H. Engin, and N. Guler
Tumor lysis syndrome following a single dose of capecitabine
Ann. Pharmacother., May 1, 2004; 38(5): 902 - 902.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Kondo, M. Terashima, A. Sato, and T. Taguchi
A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Colorectal Cancer
Jpn. J. Clin. Oncol., April 1, 2004; 34(4): 195 - 201.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Morita, M. Toi, T. Kobayashi, Y. Ito, Y. Hozumi, S. Ohno, H. Iwata, and J. Sakamoto
Application of a Continual Reassessment Method to a Phase I Clinical Trial of Capecitabine in Combination with Cyclophosphamide and Epirubicin (CEX) for Inoperable or Recurrent Breast Cancer
Jpn. J. Clin. Oncol., February 1, 2004; 34(2): 104 - 106.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
P. Gilbar
Palmar-plantar erythrodysesthesia
Journal of Oncology Pharmacy Practice, December 1, 2003; 9(4): 137 - 150.
[Abstract] [PDF]

Home page
 J Oncol Pharm PractHome page
J. E Mortimer, M. K. Lauman, B. Tan, C. L Dempsey, A. C Shillington, and K. S Hutchins
Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine
Journal of Oncology Pharmacy Practice, December 1, 2003; 9(4): 161 - 166.
[Abstract] [PDF]

Home page
 Ann OncolHome page
W. Scheithauer, J. McKendrick, S. Begbie, M. Borner, W. I. Burns, H. A. Burris, J. Cassidy, D. Jodrell, P. Koralewski, E. L. Levine, et al.
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
Ann. Onc., December 1, 2003; 14(12): 1735 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. C. Wolff, D. K. Armstrong, J. H. Fetting, M. K. Carducci, C. D. Riley, J. F. Bender, R. A. Casero Jr., and N. E. Davidson
A Phase II Study of the Polyamine Analog N1,N11-Diethylnorspermine (DENSpm) Daily for Five Days Every 21 Days in Patients with Previously Treated Metastatic Breast Cancer
Clin. Cancer Res., December 1, 2003; 9(16): 5922 - 5928.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Zhou, Z.-Y. Tang, J. Fan, Z.-Q. Wu, Y. Ji, Y.-S. Xiao, Y.-H. Shi, X.-M. Li, Q.-M. Sun, Y.-K. Liu, et al.
Capecitabine Inhibits Postoperative Recurrence and Metastasis after Liver Cancer Resection in Nude Mice with Relation to the Expression of Platelet-Derived Endothelial Cell Growth Factor
Clin. Cancer Res., December 1, 2003; 9(16): 6030 - 6037.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. H. Park, B.-Y. Ryoo, H. J. Lee, S. A. Kim, and J.-H. Chung
High incidence of severe hand-foot syndrome during capecitabine-docetaxel combination chemotherapy
Ann. Onc., November 1, 2003; 14(11): 1691 - 1692.
[Full Text] [PDF]

Home page
 JCOHome page
L. Pusztai, J. H. Zhen, B. Arun, E. Rivera, C. Whitehead, W. J. Thompson, K. M. Nealy, A. Gibbs, W. F. Symmans, F. J. Esteva, et al.
Phase I and II Study of Exisulind in Combination With Capecitabine in Patients With Metastatic Breast Cancer
J. Clin. Oncol., September 15, 2003; 21(18): 3454 - 3461.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Reichardt, G. von Minckwitz, P. C. Thuss-Patience, W. Jonat, H. Kolbl, F. Janicke, D. G. Kieback, W. Kuhn, A. E Schindler, S. Mohrmann, et al.
Multicenter phase II study of oral capecitabine (Xeloda") in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
Ann. Onc., August 1, 2003; 14(8): 1227 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Martin, M. Spielmann, M. Namer, A. duBois, C. Unger, D. Dodwell, P. Vodvarka, M. Lind, H. Calvert, A. Casado, et al.
Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines
Ann. Onc., August 1, 2003; 14(8): 1246 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Valero and G. N. Hortobagyi
Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?
J. Clin. Oncol., March 15, 2003; 21(6): 959 - 962.
[Full Text] [PDF]

Home page
 JCOHome page
T. Tominaga, H. Koyama, T. Toge, S. Miura, K. Sugimachi, S. Yamaguchi, K. Hirata, Y. Monden, Y. Nomura, M. Toi, et al.
Randomized Controlled Trial Comparing Oral Doxifluridine Plus Oral Cyclophosphamide With Doxifluridine Alone in Women With Node-Positive Breast Cancer After Primary Surgery
J. Clin. Oncol., March 15, 2003; 21(6): 991 - 998.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Salesiotis, R. Soong, R. B. Diasio, A. Frost, and K. J. Cullen
Capecitabine Induces Rapid, Sustained Response in Two Patients with Extensive Oral Verrucous Carcinoma
Clin. Cancer Res., February 1, 2003; 9(2): 580 - 585.
[Abstract] [Full Text] [PDF]